Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
734 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02388906 | Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma(CheckMate 238) | completed | Phase 3 | 906 | Bristol-Myers SquibbINDUSTRY | 25 | Apr 24, 2025 | clinicaltrials |
| NCT06223698 | Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer(SWE-Switch) | not yet recruiting | Phase 3 | 3,832 | Region Örebro CountyOTHER |
| 1 |
| Apr 20, 2025 |
| clinicaltrials |
| NCT00472459 | Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer | completed | Phase 3 | 82 | Galderma R&DINDUSTRY | 5 | Apr 18, 2025 | clinicaltrials |
| NCT03903835 | ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer(ProBio) | recruiting | Phase 3 | 750 | Karolinska InstitutetOTHER | 4 | Apr 9, 2025 | clinicaltrials |
| NCT02288247 | A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone(PRESIDE) | completed | Phase 3 | 688 | Astellas Pharma Europe Ltd.INDUSTRY | 16 | Apr 8, 2025 | clinicaltrials |
| NCT03353831 | Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer | completed | Phase 3 | 574 | AGO Research GmbHINDUSTRY | 12 | Apr 6, 2025 | clinicaltrials |
| NCT03635983 | A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma | completed | Phase 3 | 783 | Bristol-Myers SquibbINDUSTRY | 27 | Apr 1, 2025 | clinicaltrials |
| NCT00720941 | Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma(COMPARZ) | completed | Phase 3 | 1,110 | Novartis PharmaceuticalsINDUSTRY | 14 | Mar 30, 2025 | clinicaltrials |
| NCT03734016 | A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia(ALPINE) | completed | Phase 3 | 652 | BeiGeneINDUSTRY | 15 | Mar 30, 2025 | clinicaltrials |
| NCT04794777 | Comparing "Salvage" Radiotherapy and Individualized PSMA PET/CT Targeted Treatment in With Relapsing Prostate Cancer | recruiting | Phase 3 | 450 | Stefan CarlssonOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT01958021 | Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer(MONALEESA-2) | completed | Phase 3 | 668 | Novartis PharmaceuticalsINDUSTRY | 29 | Mar 7, 2025 | clinicaltrials |
| NCT04460352 | Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer(NEEDS) | recruiting | Phase 3 | 1,020 | Karolinska University HospitalOTHER | 5 | Mar 6, 2025 | clinicaltrials |
| NCT00353496 | Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours(CLARINET) | completed | Phase 3 | 264 | IpsenINDUSTRY | 15 | Mar 5, 2025 | clinicaltrials |
| NCT06565247 | Evaluation of PSMA-PET and mpMRI in High-risk Prostate Cancer - Using Histopathologic Validation | recruiting | Phase 3 | 60 | Region VästerbottenOTHER_GOV | 1 | Mar 4, 2025 | clinicaltrials |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 3 | 743 | Bristol-Myers SquibbINDUSTRY | 22 | Feb 17, 2025 | clinicaltrials |
| NCT02437318 | Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.(SOLAR-1) | completed | Phase 3 | 572 | Novartis PharmaceuticalsINDUSTRY | 31 | Feb 13, 2025 | clinicaltrials |
| NCT04778397 | Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated(ENHANCE-2) | terminated | Phase 3 | 258 | Gilead SciencesINDUSTRY | 15 | Feb 5, 2025 | clinicaltrials |
| NCT00887198 | Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 3 | 1,088 | Janssen Research & Development, LLCINDUSTRY | 11 | Feb 4, 2025 | clinicaltrials |
| NCT01715285 | A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) | completed | Phase 3 | 1,209 | Janssen Research & Development, LLCINDUSTRY | 33 | Feb 4, 2025 | clinicaltrials |
| NCT01855750 | A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma | completed | Phase 3 | 838 | Janssen Research & Development, LLCINDUSTRY | 27 | Feb 4, 2025 | clinicaltrials |
| NCT01504815 | Adaptive Radiation Treatment for Head and Neck Cancer(ARTFORCE) | completed | Phase 3 | 268 | The Netherlands Cancer InstituteOTHER | 5 | Jan 29, 2025 | clinicaltrials |
| NCT02990338 | Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients(ICARIA-MM) | completed | Phase 3 | 307 | SanofiINDUSTRY | 24 | Jan 17, 2025 | clinicaltrials |
| NCT01828099 | LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer | completed | Phase 3 | 376 | Novartis PharmaceuticalsINDUSTRY | 29 | Jan 16, 2025 | clinicaltrials |
| NCT03511664 | Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer(VISION) | completed | Phase 3 | 861 | EndocyteINDUSTRY | 10 | Jan 13, 2025 | clinicaltrials |
| NCT02151981 | AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer(AURA3) | completed | Phase 3 | 421 | AstraZenecaINDUSTRY | 18 | Jan 7, 2025 | clinicaltrials |
| NCT00418886 | Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients(ZEAL) | completed | Phase 3 | 698 | Genzyme, a Sanofi CompanyINDUSTRY | 21 | Dec 31, 2024 | clinicaltrials |
| NCT03836261 | Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL(AMPLIFY) | active not recruiting | Phase 3 | 984 | Acerta Pharma BVINDUSTRY | 27 | Dec 27, 2024 | clinicaltrials |
| NCT05477589 | Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML(SCRIPT-AML) | recruiting | Phase 3 | 170 | Vastra Gotaland RegionOTHER_GOV | 10 | Dec 19, 2024 | clinicaltrials |
| NCT00798070 | Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer Patients(PANTHER) | active not recruiting | Phase 3 | 2,017 | Karolinska University HospitalOTHER | 3 | Dec 18, 2024 | clinicaltrials |
| NCT04027309 | A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy(HOVON 156 AML) | active not recruiting | Phase 3 | 777 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 13 | Dec 17, 2024 | clinicaltrials |
| NCT06714604 | Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC(ADVANTAGE) | recruiting | Phase 3 | 432 | Sahlgrenska University HospitalOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06519266 | PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases(SCANDIUM-III) | recruiting | Phase 3 | 40 | Vastra Gotaland RegionOTHER_GOV | 1 | Nov 25, 2024 | clinicaltrials |
| NCT02919787 | Nordic Pancreatic Cancer Trial (NorPACT) - 1 | active not recruiting | Phase 2 / Phase 3 | 140 | Oslo University HospitalOTHER | 4 | Nov 20, 2024 | clinicaltrials |
| NCT02181413 | A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant | completed | Phase 3 | 656 | TakedaINDUSTRY | 33 | Nov 19, 2024 | clinicaltrials |
| NCT06044623 | Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients(IMPORTANT) | recruiting | Phase 3 | 495 | Region Örebro CountyOTHER | 6 | Nov 19, 2024 | clinicaltrials |
| NCT02950155 | A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis(Rinomax) | completed | Phase 3 | 47 | Fredrik PiehlOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT03053440 | A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)(ASPEN) | completed | Phase 3 | 201 | BeiGeneINDUSTRY | 12 | Oct 26, 2024 | clinicaltrials |
| NCT05744219 | Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial(IRIS) | recruiting | Phase 3 | 338 | Jon UnossonOTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT03240523 | A Study to Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 5) | terminated | Phase 3 | 766 | BayerINDUSTRY | 23 | Oct 18, 2024 | clinicaltrials |
| NCT04428333 | Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma(INDUCE-4) | terminated | Phase 3 | 117 | GlaxoSmithKlineINDUSTRY | 19 | Oct 9, 2024 | clinicaltrials |
| NCT00072462 | Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ(IBIS-II DCIS) | completed | Phase 3 | 2,980 | Queen Mary University of LondonOTHER | 14 | Sep 19, 2024 | clinicaltrials |
| NCT01607957 | Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies(RECOURSE) | completed | Phase 3 | 800 | Taiho Oncology, Inc.INDUSTRY | 13 | Sep 19, 2024 | clinicaltrials |
| NCT04332822 | A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma(POLAR BEAR) | recruiting | Phase 3 | 300 | Nordic Lymphoma GroupNETWORK | 7 | Sep 19, 2024 | clinicaltrials |
| NCT06248996 | a Multicentre Phase III Study of Risk-based Treatment Intensification With Hyperfractionated Radiotherapy in Head and Neck Cancer Patients(ARTSCAN VI) | recruiting | Phase 3 | 308 | Lund University HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04385368 | Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)(MERMAID-1) | completed | Phase 3 | 89 | AstraZenecaINDUSTRY | 33 | Aug 30, 2024 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials